Study of Drug Acceptance & Its Persistence Over Time in Patients Receiving

Status Recruiting

Clinical Trial Summary

Allograft patients have a complex care pathway and are left with a large number of prescribed medications. They have to deal with changes linked to the transplant (change in taste, fatigue, regular monitoring, risk of GVH (graft versus host) complications, infectious risks, change in eating habits, etc.), and a large number of associated drugs (immunosuppressants, anti-infectious prophylaxis and supplements (folic acid, magnesium, bile salts, etc.), which are added to any pre-existing chronic pathologies. Therapeutic adherence of these patients is a real challenge. Indeed, the success of the transplant and the complications that may arise (graft rejection, GVH, infections, death, hospitalisation, etc.) are closely linked to good or poor therapeutic adherence. Moreover, the majority of these patients are young and are not used to taking many treatments, which will change after the transplant. Adherence to treatment consists of three phases: - Acceptance of the disease and the benefits of treatment, - Compliance: following the instructions of the prescription (dosage and schedule), - Persistence: consistency of compliance over time. Support from the care team throughout the management of these patients is necessary for good therapeutic adherence in order to prevent and act early on the difficulties encountered (appearance of side effects linked to the treatments, large number of tablets per day, duration of treatment (1 to 2 years), risk of GVH, significant asthenia and difficulty in concentrating, etc.) We have a large amount of data on therapeutic adherence and potential non-adherence factors in patients with chronic diseases (diabetes, asthma, cancer, etc.) or in solid organ transplant patients. On the other hand, there is little data on allograft patients. Most often, a parallel is made between the data present in kidney transplant patients and allograft patients. However, it is necessary to study more specifically the therapeutic adherence in this population. A recent multicentre cross-sectional study in France on adherence in allograft patients showed that 80% of adult and paediatric patients were not adherent.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Allograft

Clinical Trial Details

NCT number	NCT05164835
Study type	Interventional
Source	University Hospital, Limoges
Contact	Jérémy JOST, PhamD, PhD
Phone	+33(0)555 056 155
Email	jeremy.jost@chu-limoges.fr
Status	Recruiting
Phase	N/A
Start date	January 17, 2022
Completion date	January 20, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05536492` - Sticky Bone Compared to A-PRF(Platlet Rich Fibrin) Effect on Alveolar Ridge Preservation	N/A
Completed	`NCT00384540` - Cardiac Allograft Vasculopathy and Dobutamine Stress Echocardiography / Brain Natriuretic Peptide Coupling	N/A
Recruiting	`NCT02882828` - PK Assessment of Tacrolimus Exposure Before and After a Switch From Twice Daily Immediate-release (Prograf®) to Once-daily Prolonged Release Tacrolimus (Envarsus®)	Phase 4
Completed	`NCT02444052` - Evaluation of Zimmer Puros® Allograft vs. Creos™ Allograft for Alveolar Ridge Preservation	N/A
Terminated	`NCT04021316` - Decellularised Dermis Allograft for the Treatment of Chronic Venous Leg Ulceration	N/A
Completed	`NCT00894049` - A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation	Phase 2
Recruiting	`NCT03402776` - Impact of a Fourth Hexavalent Vaccine After Hematopoietic Stem Cell Transplantation	Phase 3
Completed	`NCT03829072` - Cooking Education and Adapted Physical Activity in Allografted Patients	N/A
Completed	`NCT03009708` - Feasibility Study of Platelet Activation and Inflammatory Response of Platelets in Hematopoietic Stem Cell Allograft Patients Post-transplant: Spontaneously and After Stimulation by an CMV Antigen	N/A
Terminated	`NCT05258929` - RElapse After Allograft: Link Between LoCus of Control and QualiTy of Life
Recruiting	`NCT05096351` - Immunological Reaction of the Recipient After Cold-stored Saphenous Venous Allograft (Bioprotec)
Not yet recruiting	`NCT05459181` - HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC)	N/A
Recruiting	`NCT05510011` - Allograft and Tantalum Cone Reconstruction in TKA Revision
Not yet recruiting	`NCT06219473` - Efficacy of Fascia Lata Allograft and Platelet Rich Fibrin on the Periodontal Phenotype Around Dental Implant	Phase 4
Withdrawn	`NCT05423496` - KidneyCare Immuno-optimization in Renal Allografts (KIRA)	N/A
Completed	`NCT00876148` - Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study of Drug Acceptance and Its Persistence Over Time in Patients Receiving a Haematopoietic Stem Cell Allograft — AdHemLim

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms